| This week's sponsor is DIA. | | | |
Featured Story Friday, March 24, 2017 During his budget blueprint announced earlier this month, President Donald Trump announced swingeing cutbacks across federal programs, with the National Institutes of Health (NIH) set for a $5.8 billion slashing. Top Stories Friday, March 24, 2017 Novartis has offloaded two mid-phase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to the age-related deterioration of the immune system. Thursday, March 23, 2017 Fierce 15 winner C4 Therapeutics has become the latest biopharma to strike a deal with the Google-backed life sciences company Calico, although true to its quiet nature few details about the pact have emerged. Friday, March 24, 2017 A phase 2 trial of Xenon Pharmaceuticals’ acne candidate XEN801 has missed its primary and key secondary efficacy endpoints. The comprehensive failure prompted Xenon to admit the data don’t support continued development of XEN801 and wiped 44% off its stock price in premarket trading. Friday, March 24, 2017 Eighteen months ago, Eli Lilly cut a $53 million deal with Ignyta setting up an alliance to develop cancer therapy taladegib. Now, the San Diego-based biotech has followed through on plans to pare down the alliance and focus more on another drug. Thursday, March 23, 2017 Pfizer and Merck KGaA are officially fourth to market with their checkpoint inhibitor Bavencio (avelumab)—but first with approval to target a rare, aggressive form of skin cancer, Merkel cell carcinoma. Thursday, March 23, 2017 In this week's EuroBiotech Report, AstraZeneca is rejected by FDA, Novartis fails phase 3, Pulmocide raises $30 million and more. Friday, March 24, 2017 China plans to eliminate some major regulatory barriers in front of foreign drugs, Tessa bought Euchloe for its checkpoint inhibitors, and Johnson & Johnson and Lilly CEOs expressed support for international trade. Thursday, March 23, 2017 Former FDA chief Robert Califf has gone back to Duke University and will lead a PCORI-backed research foundation, ex-Shire exec Shepard jumped to Eisai's oncology business, and Forty Seven hired former Sandoz exec McCamish as new CEO. Plus more hirings, firings and retirings throughout the industry. | This week's sponsor is Destination Medical Center. | | | Destination Medical Center (DMC) is a 20-year, $5.6 billion economic development plan set to transform Rochester, MN. DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. |
| | | The CHMP has this month recommended six medicines for approval in Europe, including three orphan meds, but also said that PTC has withdrawn its app for Translarna (ataluren) to treat cystic fibrosis. Release Ampio Pharmaceuticals has "expressed substantial doubt as to its ability to continue as a going concern," according to a recent filing. Denver Business Journal story Valeritas Holdings, which markets a device that delivers insulin therapy for diabetes, has raised $53 million from its Nasdaq IPO. Renaissance Capital story | |
|
Resources Sponsored By: Veeva This white paper focuses on engaging healthcare stakeholders effectively while integrating your medical and commercial teams. Presented By: Veeva Share your thoughts on the life sciences industry’s progress in reducing system and process complexity to improve study execution. The first 50 qualified respondents will receive a $10 Amazon gift card, as well as a $10 donation made to Doctors Without Borders in their name. Finish the survey today! Presented By: Enterprise Florida As life sciences companies decide to implement shared services, a major concern is real estate costs for a facility. Download this Whitepaper to learn why Florida is gaining traction as a prime location for shared services. MIXiii-BIOMED 2017 May 23-25, 2017 | Tel Aviv, Israel Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA |
